EuroscreenFast and GW Vitek announce distribution partnership in Korea

According to the agreement, GW Vitek will represent EuroscreenFast’s  discovery and lead optimisation capabilities in the Republic of Korea. While EuroscreenFast has had some presence in East-Asia, this partnership will enable significant expansion of its commercial reach into the Korean market. Through the leveraging of GW Vitek’s extensive distribution network and market expertise, EuroscreenFast aims to provide its cutting-edge GPCR cell-based assay services and a robust deorphanisation offering to a broader range of clients.

“This partnership with EuroscreenFast further strengthens GW Vitek’s position as Korea’s go-to provider of biotherapeutic research solutions for both biologics and chemical therapeutics,” said Jaewon Yang, CEO at GW Vitek. “We are excited to offer EuroscreenFast’s advanced GPCR screening technologies to our clients, which is a new area of expansion for our already broad catalogue of instruments and wet-lab services.” the CRO EuroscreenFast has been a pioneer in GPCR science for more than 30 years, offering over 1,000 functional assays across more than 530 GPCR and other targets. EuroscreenFast also boasts a deorphanisation track record with the identification of 17 natural receptor-ligand pairs. Custom assay development and specialised tools to bridge the gap between in vitro and in vivo data are even more reasons why therapeutic developers worldwide know that EuroscreenFast is the unrivalled GPCR development partner. EuroscreenFast is a business unit of Epics Therapeutics SA.